开云app官网登录入口网页版-官方正版

#长期疗效#

89篇内容 | 2435人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2150517, encodeId=8a48215051e74, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a> 药物性鼻炎 (Rhinitis medicamentosa， RM) 是一种由药物引起的鼻炎，病因是过度使用外用鼻腔药物。鼻腔外用药物最常见的是鼻腔减充血剂，但也可能包括可卡因等其他药物。这种病症最初是在历史病例报告中发现的，报告称患者对鼻腔减充血剂上瘾。据报道，RM 在三级耳鼻喉科的发病率为 1% 至 9%。这可能大大低估了该病的真实发病率，因为在社区自行用药或在全科诊所接受治疗的患者都可能没有得到正式诊断。, objectTitle=长期疗效, objectType=topic, longId=97028, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=46, createdTime=2023-07-30, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1553540, encodeId=6818155354094, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=Neurology：难治性局灶性癫痫患者辅助性塞诺巴胺的长期疗效和安全性研究, objectType=article, longId=738700, objectId=3adfe3870050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3adfe3870050, replyNumber=0, likeNumber=0, createdTime=2022-09-10, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3adfe3870050, moduleTitle=Neurology：难治性局灶性癫痫患者辅助性塞诺巴胺的长期疗效和安全性研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3adfe3870050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553538, encodeId=d2971553538c2, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=Neurology：波尼莫德治疗复发缓解型多发性硬化症的长期疗效, objectType=article, longId=737090, objectId=30bee3709037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30bee3709037, replyNumber=0, likeNumber=93, createdTime=2022-08-28, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30bee3709037, moduleTitle=Neurology：波尼莫德治疗复发缓解型多发性硬化症的长期疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=30bee3709037)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553539, encodeId=91df155353929, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=J Eur Acad Dermatol Venereol：Brodalumab治疗中重度斑块状银屑病的长期疗效和安全性 , objectType=article, longId=736658, objectId=f14be366588f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f14be366588f, replyNumber=0, likeNumber=88, createdTime=2022-08-24, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f14be366588f, moduleTitle=J Eur Acad Dermatol Venereol：Brodalumab治疗中重度斑块状银屑病的长期疗效和安全性 , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f14be366588f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553537, encodeId=8b5b155353e32, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=J Clin Oncol：B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效, objectType=article, longId=301786, objectId=fb92301e86b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb92301e86b3, replyNumber=0, likeNumber=76, createdTime=2022-03-29, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb92301e86b3, moduleTitle=J Clin Oncol：B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fb92301e86b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553536, encodeId=d8c315535369e, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=Arthritis Rheumatol：单克隆抗体Guselkumab治疗活动性银屑病的长期疗效和安全性, objectType=article, longId=301766, objectId=95c3301e667c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95c3301e667c, replyNumber=0, likeNumber=107, createdTime=2022-03-28, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95c3301e667c, moduleTitle=Arthritis Rheumatol：单克隆抗体Guselkumab治疗活动性银屑病的长期疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=95c3301e667c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553535, encodeId=be621553535fd, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=Rheumatology：Apremilast单药治疗DMARD无效的活动性银屑病关节炎的长期疗效, objectType=article, longId=301742, objectId=ea63301e42f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea63301e42f2, replyNumber=0, likeNumber=63, createdTime=2022-03-28, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea63301e42f2, moduleTitle=Rheumatology：Apremilast单药治疗DMARD无效的活动性银屑病关节炎的长期疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ea63301e42f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553534, encodeId=c82c15535347e, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, objectType=article, longId=301707, objectId=d31c301e07bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31c301e07bd, replyNumber=0, likeNumber=70, createdTime=2022-03-28, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31c301e07bd, moduleTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d31c301e07bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553533, encodeId=e2bb1553533bd, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效, objectType=article, longId=301380, objectId=19cc301380e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19cc301380e9, replyNumber=0, likeNumber=93, createdTime=2022-03-23, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19cc301380e9, moduleTitle=Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=19cc301380e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553532, encodeId=2121155353219, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=IBD:口服麦芽酚铁与静脉注射羧基麦芽糖铁治疗炎症性肠病患者缺铁性贫血的长期疗效分析, objectType=article, longId=300159, objectId=c11a300159d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c11a300159d5, replyNumber=0, likeNumber=0, createdTime=2022-03-08, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c11a300159d5, moduleTitle=IBD:口服麦芽酚铁与静脉注射羧基麦芽糖铁治疗炎症性肠病患者缺铁性贫血的长期疗效分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c11a300159d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553531, encodeId=57cb155353180, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=Sci Rep：52周的Dupilumab治疗中重度特应性皮炎的长期疗效和安全性研究, objectType=article, longId=299023, objectId=2d572990238b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d572990238b, replyNumber=0, likeNumber=78, createdTime=2022-02-19, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d572990238b, moduleTitle=Sci Rep：52周的Dupilumab治疗中重度特应性皮炎的长期疗效和安全性研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2d572990238b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553530, encodeId=c04915535308d, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=Eur Urol Focus：前列腺铥激光剜除术的长期疗效如何？, objectType=article, longId=294488, objectId=d066294488f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d066294488f5, replyNumber=0, likeNumber=93, createdTime=2022-01-23, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d066294488f5, moduleTitle=Eur Urol Focus：前列腺铥激光剜除术的长期疗效如何？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d066294488f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553529, encodeId=8f601553529f4, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=J. Clin. Med：依鲁替尼治疗 CLL 患者的长期疗效和安全性：真实生活体验。 , objectType=article, longId=293868, objectId=f6e9293868c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6e9293868c5, replyNumber=0, likeNumber=82, createdTime=2022-01-13, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6e9293868c5, moduleTitle=J. Clin. Med：依鲁替尼治疗 CLL 患者的长期疗效和安全性：真实生活体验。 , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f6e9293868c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553528, encodeId=44b61553528c2, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=JCEM：乙醇消融治疗甲状腺乳头状癌转移淋巴结的长期疗效, objectType=article, longId=292415, objectId=4933292415fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4933292415fb, replyNumber=0, likeNumber=116, createdTime=2021-12-22, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4933292415fb, moduleTitle=JCEM：乙醇消融治疗甲状腺乳头状癌转移淋巴结的长期疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4933292415fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553527, encodeId=e028155352e81, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响, objectType=article, longId=220337, objectId=e64222033e7d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e64222033e7d, replyNumber=0, likeNumber=101, createdTime=2021-11-16, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e64222033e7d, moduleTitle=Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e64222033e7d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553526, encodeId=c1c91553526ae, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=J Thorac Oncol：纳武单抗+伊匹单抗治疗晚期非小细胞肺癌的长期疗效, objectType=article, longId=218857, objectId=7f8121885e24, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f8121885e24, replyNumber=0, likeNumber=81, createdTime=2021-10-20, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f8121885e24, moduleTitle=J Thorac Oncol：纳武单抗+伊匹单抗治疗晚期非小细胞肺癌的长期疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7f8121885e24)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553525, encodeId=eac91553525bf, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=Cancers：早期乳腺癌患者新辅助放化疗的长期疗效和安全性, objectType=article, longId=218811, objectId=ff98218811b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff98218811b1, replyNumber=0, likeNumber=71, createdTime=2021-10-20, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff98218811b1, moduleTitle=Cancers：早期乳腺癌患者新辅助放化疗的长期疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ff98218811b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553524, encodeId=f7ea1553524e2, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=Br J Clin Pharmacol：非瓣膜性房颤遇上肝病，直接口服抗凝剂的使用和长期疗效, objectType=article, longId=217659, objectId=afdf21e659f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afdf21e659f3, replyNumber=0, likeNumber=73, createdTime=2021-09-27, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afdf21e659f3, moduleTitle=Br J Clin Pharmacol：非瓣膜性房颤遇上肝病，直接口服抗凝剂的使用和长期疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=afdf21e659f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553523, encodeId=cdde15535231f, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=Blood：维奈托克+利妥昔单抗治疗复发性CLL的长期疗效, objectType=article, longId=217177, objectId=f20e21e177df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f20e21e177df, replyNumber=0, likeNumber=78, createdTime=2021-09-17, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f20e21e177df, moduleTitle=Blood：维奈托克+利妥昔单抗治疗复发性CLL的长期疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f20e21e177df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553522, encodeId=a5d0155352260, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, objectTitle=JAAD:Ixekizumab 的长期疗效和安全性, objectType=article, longId=216744, objectId=ea16216e443b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea16216e443b, replyNumber=0, likeNumber=99, createdTime=2021-09-08, rootId=0, userName=gjsgj, userId=fe2a14383573, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea16216e443b, moduleTitle=JAAD:Ixekizumab 的长期疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ea16216e443b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

长期疗效

2020-05-29

yangchou (审核中...)

前往app查看评论内容

全文收起 #长期疗效# 药物性鼻炎 (Rhinitis medicamentosa， RM) 是一种由药物引起的鼻炎，病因是过度使用外用鼻腔药物。鼻腔外用药物最常见的是鼻腔减充血剂，但也可能包括可卡因等其他药物。这种病症最初是在历史病例报告中发现的，报告称患者对鼻腔减充血剂上瘾。据报道，RM 在三级耳鼻喉科的发病率为 1% 至 9%。这可能大大低估了该病的真实发病率，因为在社区自行用药或在全科诊所接受治疗的患者都可能没有得到正式诊断。

2023-07-30发表于浙江省

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

Neurology：难治性局灶性癫痫患者辅助性塞诺巴胺的长期疗效和安全性研究

2022-09-10

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

Neurology：波尼莫德治疗复发缓解型多发性硬化症的长期疗效

2022-08-28

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

J Eur Acad Dermatol Venereol：Brodalumab治疗中重度斑块状银屑病的长期疗效和安全性

2022-08-24

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

J Clin Oncol：B细胞成熟抗原和CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期疗效

2022-03-29

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

Arthritis Rheumatol：单克隆抗体Guselkumab治疗活动性银屑病的长期疗效和安全性

2022-03-28

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

Rheumatology：Apremilast单药治疗DMARD无效的活动性银屑病关节炎的长期疗效

2022-03-28

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效

2022-03-28

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效

2022-03-23

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

IBD:口服麦芽酚铁与静脉注射羧基麦芽糖铁治疗炎症性肠病患者缺铁性贫血的长期疗效分析

2022-03-08

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

Sci Rep：52周的Dupilumab治疗中重度特应性皮炎的长期疗效和安全性研究

2022-02-19

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

Eur Urol Focus：前列腺铥激光剜除术的长期疗效如何？

2022-01-23

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

J. Clin. Med：依鲁替尼治疗 CLL 患者的长期疗效和安全性：真实生活体验。

2022-01-13

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

JCEM：乙醇消融治疗甲状腺乳头状癌转移淋巴结的长期疗效

2021-12-22

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响

2021-11-16

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

J Thorac Oncol：纳武单抗+伊匹单抗治疗晚期非小细胞肺癌的长期疗效

2021-10-20

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

Cancers：早期乳腺癌患者新辅助放化疗的长期疗效和安全性

2021-10-20

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

Br J Clin Pharmacol：非瓣膜性房颤遇上肝病，直接口服抗凝剂的使用和长期疗效

2021-09-27

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

Blood：维奈托克+利妥昔单抗治疗复发性CLL的长期疗效

2021-09-17

gjsgj (审核中...)

前往app查看评论内容

#长期疗效#

JAAD:Ixekizumab 的长期疗效和安全性

2021-09-08

科室
- - 订阅+
  - 更多科室
工具
服务